Our leadership team, including recognized physician experts and researchers, is at the forefront of shaping new standards of cancer care based upon the latest research. Patients are at the heart of everything we do. Sarah Cannon offers integrated cancer services, providing patients with cutting-edge treatments and upholding the highest quality care for patients from diagnosis through survivorship.
Todd Bauer, MD
Associate Director, Drug Development; Principal Investigator
Dr. Bauer joined Sarah Cannon as an investigator in July 2012, and became the associate director of drug development in December 2014. In his role, he provides care for patients using cutting-edge drugs and helps to shape the ways in which these new agents will be given to all patients after approval. These treatments include molecularly targeted therapies, immunomodulatory agents, and novel chemotherapeutics.
Additionally, he serves as the clinical lead for our molecular profiling and precision medicine initiatives, utilizing next generation sequencing and other molecular analysis to better match patients to effective therapies. While he treats tumors of all varieties, he has a special interest in lung cancer. He received his undergraduate degree from Saint Louis University and his medical degree from Loyola University Chicago. He completed his internship, residency and chief residency at Vanderbilt University before his fellowship training at The Ohio State University. Bauer is board certified in Medical Oncology and Internal Medicine. Additionally, he is an associate with Tennessee Oncology, PLLC.